Orlistat reduces weight but its cost-effectiveness remains unclear

Evidence-Based Nursing

Volumn 16, Issue 2, 2013, Pages 56-57

  Veerman, Lennert ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880297649     PISSN: 13676539     EISSN: 14689618     Source Type: Journal    
DOI: 10.1136/eb-2012-100958     Document Type: Article

References (5)

1. Neovius M, Narbro K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obes (Lond) 2008;32:1752-63.
2. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.
3. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9.
4. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.
5. Ara R, Brennan A. The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries. Obesity Rev 2007;8:363-71.